Abstract: Some disclosed embodiments are directed to obtaining a decoded audio data including a spoken language utterance recognized in audio data and identifying a disfluency in the decoded audio data. Upon determining that correcting the disfluency would improve a readability score of the decoded audio data, the system generates a particular correction to correct the disfluency and applies the particular correction to the decoded audio data. Then, an updated decoded audio data is generated which reflects the particular correction. The updated decoded audio data has improved readability over the decoded audio data.

Abstract: Systems are configured to obtain streaming audio data comprising language utterances, continuously decode the streaming audio data in order to generate decoded streaming audio data and determine whether a linguistic boundary exists within an initial segment of decoded streaming audio data. When a linguistic boundary is determined to exist, the systems apply a punctuation at the linguistic boundary and output a first portion of the initial segment of the streaming audio data ending at the linguistic boundary while refraining from outputting a second portion of the initial segment which is located temporally subsequent to the first portion of the initial segment. Systems are also configured to delay the output until predetermined punctuation validation processes have been performed.

Abstract: Provided herein are controlled release gastro retentive dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile.

Abstract: Provided herein are controlled release multiparticulate dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile.

Abstract: The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.

Abstract: The present disclosure relates to use of pulsed dose inhaled nitric oxide for treatment of infection, including infection with SARS-CoV2 and the disease state COVID-19.

Abstract: Described are methods for improving oxygen saturation in patients suffering from hypoxemia, wherein said patients are receiving a continuous flow of oxygen at 10 L/min and exhibit an initial oxygen saturation of at least about 88%, comprising administering inhaled nitric oxide to said patients in an outpatient setting. Methods for improving quality of life for a hospitalized patient, reducing patient hospitalization time, and reducing costs associated with patient hospitalization are also described.

Abstract: Described are methods for reducing pulmonary resistance, reducing pulmonary pressure, and increasing pulmonary arterial compliance by providing a inhaled nitric oxide.

Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

Abstract: Described are methods for treatment of hypertension in combination with pulsed, inhaled nitric oxide.

Abstract: Described are methods for maintaining or improving activity levels in patients lung-related conditions.

Abstract: Oral dosage forms comprising eltrombopag choline, processes for preparation thereof and methods of use thereof are disclosed. The compositions disclosed exhibit enhanced bioavailability and reduced food effect compared to commercially available formulations of eltrombopag.

Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

Abstract: Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide. The nasal cannulas may reduce the total volume and potential for retrograde flow during nitric oxide therapy through the design of the specific dimensions of the flow path and/or having check valves in the nitric oxide delivery line and/or having a flapper or umbrella valve dedicated to nitric oxide delivery. The nasal cannulas may also use materials that limit oxygen diffusion through the cannula walls. The nosepiece for these cannulas may be manufactured by a molding technique.

Abstract: Described are methods for providing a pulsed dose of nitric oxide during at least the first two-thirds of total inspiratory time in each single breath for a therapeutically relevant period of time.

Abstract: Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide. The nasal cannulas may reduce the total volume and potential for retrograde flow during nitric oxide therapy through the design of the specific dimensions of the flow path and/or having check valves in the nitric oxide delivery line and/or having a flapper or umbrella valve dedicated to nitric oxide delivery. The nasal cannulas may also use materials that limit oxygen diffusion through the cannula walls. The nosepiece for these cannulas may be manufactured by a molding technique.

Abstract: Described herein are methods of treating pulmonary hypertension by maintaining dosing frequency and/or minimizing skipped breaths during pulsed administration of inhaled nitric oxide.

Abstract: Described herein are methods of using inhaled nitric oxide for treating pulmonary hypertension, improving exercise capacity and/or reducing oxygen desaturation in a patient.